Literature DB >> 26082084

The high-density lipoprotein-adjusted SCORE model worsens SCORE-based risk classification in a contemporary population of 30,824 Europeans: the Copenhagen General Population Study.

Martin B Mortensen1, Shoaib Afzal2, Børge G Nordestgaard3, Erling Falk1.   

Abstract

AIMS: Recent European guidelines recommend to include high-density lipoprotein (HDL) cholesterol in risk assessment for primary prevention of cardiovascular disease (CVD), using a SCORE-based risk model (SCORE-HDL). We compared the predictive performance of SCORE-HDL with SCORE in an independent, contemporary, 'low-risk' European population, focusing on ability to identify those in need of intensified CVD prevention. METHODS AND
RESULTS: Between 2003 and 2008, 46,092 individuals without CVD, diabetes, or statin use were enrolled in the Copenhagen General Population Study (CGPS). During a mean of 6.8 years of follow-up, 339 individuals died of CVD. In the SCORE target population (age 40-65; n = 30,824), fewer individuals were at baseline categorized as high risk (≥5% 10-year risk of fatal CVD) using SCORE-HDL compared with SCORE (10 vs. 17% in men, 1 vs. 3% in women). SCORE-HDL did not improve discrimination of future fatal CVD, compared with SCORE, but decreased the detection rate (sensitivity) of the 5% high-risk threshold from 42 to 26%, yielding a negative net reclassification index (NRI) of -12%. Importantly, using SCORE-HDL, the sensitivity was zero among women. Both SCORE and SCORE-HDL overestimated risk of fatal CVD. In well-calibrated models developed from the CGPS, HDL did not improve discrimination or NRI. Lowering the decision threshold from 5 to 1% led to progressive gain in NRI for both CVD mortality and morbidity.
CONCLUSION: SCORE-HDL did not improve discrimination compared with SCORE, but deteriorated risk classification based on NRI. Future guidelines should consider lower decision thresholds and prioritize CVD morbidity and people above age 65.
© The Author 2015. Published by Oxford University Press on behalf of the European Society of Cardiology.

Entities:  

Keywords:  Copenhagen General Population Study; HDL; SCORE; risk assessment

Mesh:

Substances:

Year:  2015        PMID: 26082084      PMCID: PMC4576144          DOI: 10.1093/eurheartj/ehv251

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  17 in total

1.  Predictive accuracy of the SCORE risk function for cardiovascular disease in clinical practice: a prospective evaluation of 44 649 Austrian men and women.

Authors:  Hanno Ulmer; Barbara Kollerits; Cecily Kelleher; Günter Diem; Hans Concin
Journal:  Eur J Cardiovasc Prev Rehabil       Date:  2005-10

2.  ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).

Authors:  Zeljko Reiner; Alberico L Catapano; Guy De Backer; Ian Graham; Marja-Riitta Taskinen; Olov Wiklund; Stefan Agewall; Eduardo Alegria; M John Chapman; Paul Durrington; Serap Erdine; Julian Halcox; Richard Hobbs; John Kjekshus; Pasquale Perrone Filardi; Gabriele Riccardi; Robert F Storey; David Wood
Journal:  Eur Heart J       Date:  2011-06-28       Impact factor: 29.983

3.  Nonfasting triglycerides, cholesterol, and ischemic stroke in the general population.

Authors:  Anette Varbo; Børge G Nordestgaard; Anne Tybjaerg-Hansen; Peter Schnohr; Gorm B Jensen; Marianne Benn
Journal:  Ann Neurol       Date:  2011-02-18       Impact factor: 10.422

4.  How much does HDL cholesterol add to risk estimation? A report from the SCORE Investigators.

Authors:  Marie Therese Cooney; Alexandra Dudina; Dirk De Bacquer; Anthony Fitzgerald; Ronan Conroy; Susana Sans; Alessandro Menotti; Guy De Backer; Pekka Jousilahti; Ulrich Keil; Troels Thomsen; Peter Whincup; Ian Graham
Journal:  Eur J Cardiovasc Prev Rehabil       Date:  2009-06

5.  Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project.

Authors:  R M Conroy; K Pyörälä; A P Fitzgerald; S Sans; A Menotti; G De Backer; D De Bacquer; P Ducimetière; P Jousilahti; U Keil; I Njølstad; R G Oganov; T Thomsen; H Tunstall-Pedoe; A Tverdal; H Wedel; P Whincup; L Wilhelmsen; I M Graham
Journal:  Eur Heart J       Date:  2003-06       Impact factor: 29.983

6.  European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice.

Authors:  Guy De Backer; Ettore Ambrosioni; Knut Borch-Johnsen; Carlos Brotons; Renata Cifkova; Jean Dallongeville; Shah Ebrahim; Ole Faergeman; Ian Graham; Giuseppe Mancia; Volkert Manger Cats; Kristina Orth-Gomér; Joep Perk; Kalevi Pyörälä; José L Rodicio; Susana Sans; Vedat Sansoy; Udo Sechtem; Sigmund Silber; Troels Thomsen; David Wood
Journal:  Eur Heart J       Date:  2003-09       Impact factor: 29.983

7.  HDL cholesterol protects against cardiovascular disease in both genders, at all ages and at all levels of risk.

Authors:  M T Cooney; A Dudina; D De Bacquer; L Wilhelmsen; S Sans; A Menotti; G De Backer; P Jousilahti; U Keil; T Thomsen; P Whincup; I M Graham
Journal:  Atherosclerosis       Date:  2009-03-19       Impact factor: 5.162

8.  The ability of the SCORE high-risk model to predict 10-year cardiovascular disease mortality in Norway.

Authors:  Anja S Lindman; Marit B Veierød; Jan I Pedersen; Aage Tverdal; Inger Njølstad; Randi Selmer
Journal:  Eur J Cardiovasc Prev Rehabil       Date:  2007-08

9.  European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts).

Authors:  Joep Perk; Guy De Backer; Helmut Gohlke; Ian Graham; Zeljko Reiner; Monique Verschuren; Christian Albus; Pascale Benlian; Gudrun Boysen; Renata Cifkova; Christi Deaton; Shah Ebrahim; Miles Fisher; Giuseppe Germano; Richard Hobbs; Arno Hoes; Sehnaz Karadeniz; Alessandro Mezzani; Eva Prescott; Lars Ryden; Martin Scherer; Mikko Syvänne; Wilma J M Scholte op Reimer; Christiaan Vrints; David Wood; Jose Luis Zamorano; Faiez Zannad
Journal:  Eur Heart J       Date:  2012-05-03       Impact factor: 29.983

10.  The effect of elevated body mass index on ischemic heart disease risk: causal estimates from a Mendelian randomisation approach.

Authors:  Børge G Nordestgaard; Tom M Palmer; Marianne Benn; Jeppe Zacho; Anne Tybjaerg-Hansen; George Davey Smith; Nicholas J Timpson
Journal:  PLoS Med       Date:  2012-05-01       Impact factor: 11.069

View more
  15 in total

1.  Statin Use in Primary Prevention of Atherosclerotic Cardiovascular Disease According to 5 Major Guidelines for Sensitivity, Specificity, and Number Needed to Treat.

Authors:  Martin Bødtker Mortensen; Børge Grønne Nordestgaard
Journal:  JAMA Cardiol       Date:  2019-11-01       Impact factor: 14.676

2.  2016 European Guidelines on cardiovascular disease prevention in clinical practice : The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts).

Authors:  Massimo F Piepoli
Journal:  Int J Behav Med       Date:  2017-06

Review 3.  Which Lipids Should Be Analyzed for Diagnostic Workup and Follow-up of Patients with Hyperlipidemias?

Authors:  Michel R Langlois; Børge G Nordestgaard
Journal:  Curr Cardiol Rep       Date:  2018-08-17       Impact factor: 2.931

4.  High Density Lipoproteins: Is There a Comeback as a Therapeutic Target?

Authors:  Arnold von Eckardstein
Journal:  Handb Exp Pharmacol       Date:  2022

5.  2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR).

Authors:  Massimo F Piepoli; Arno W Hoes; Stefan Agewall; Christian Albus; Carlos Brotons; Alberico L Catapano; Marie-Therese Cooney; Ugo Corrà; Bernard Cosyns; Christi Deaton; Ian Graham; Michael Stephen Hall; F D Richard Hobbs; Maja-Lisa Løchen; Herbert Löllgen; Pedro Marques-Vidal; Joep Perk; Eva Prescott; Josep Redon; Dimitrios J Richter; Naveed Sattar; Yvo Smulders; Monica Tiberi; H Bart van der Worp; Ineke van Dis; W M Monique Verschuren; Simone Binno
Journal:  Eur Heart J       Date:  2016-05-23       Impact factor: 29.983

6.  Extensive carotid atherosclerosis and the diagnostic accuracy of coronary risk calculators.

Authors:  Michel Romanens; Martin Bødtker Mortensen; Isabella Sudano; Thomas Szucs; Ansgar Adams
Journal:  Prev Med Rep       Date:  2017-03-14

7.  ACC/AHA guidelines superior to ESC/EAS guidelines for primary prevention with statins in non-diabetic Europeans: the Copenhagen General Population Study.

Authors:  Martin Bødtker Mortensen; Børge G Nordestgaard; Shoaib Afzal; Erling Falk
Journal:  Eur Heart J       Date:  2017-02-21       Impact factor: 29.983

8.  Cystatin C as a Candidate Biomarker of Cardiovascular Outcomes: Too Near, but too Far from Reality.

Authors:  Luiz Sérgio F de Carvalho; Thiago Quinaglia Ac Silva; Otávio Rizzi Coelho-Filho
Journal:  Arq Bras Cardiol       Date:  2018-12       Impact factor: 2.000

9.  Statin use and cardiovascular risk factors in diabetic patients developing a first myocardial infarction.

Authors:  Martin Bødtker Mortensen; Imra Kulenovic; Erling Falk
Journal:  Cardiovasc Diabetol       Date:  2016-05-27       Impact factor: 9.951

10.  Limitations of the SCORE-guided European guidelines on cardiovascular disease prevention.

Authors:  Martin Bødtker Mortensen; Erling Falk
Journal:  Eur Heart J       Date:  2017-08-01       Impact factor: 29.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.